UH3DK122644
Cooperative Agreement
Overview
Grant Description
Microphysiological systems for modeling autoimmunity in type 1 diabetes - Summary
This proposal leverages our group’s complementary expertise in tissue-on-a-chip technology, immunology, pluripotent cell derivation and differentiation, and islet biology to create robust systems containing human islet cells, immune cells, and other features to recapitulate the process of islet autoimmunity in type I diabetes (T1D).
The UG3 phase of this proposal will improve upon already-robust microdevices and develop new cell lines and assays that will enable studies of autoimmunity in an isogenic setting. The UH3 phase of this proposal will exploit these tools and platforms to develop isogenic models that can be used to study immune-islet interactions. The focus of the UH3 phase will be to investigate the determinants of islet infiltration and killing, and to determine the effects of mutations in T1D-associated genes on this process.
In addition, these in vitro systems will be used to pilot the use of cellular therapies to interrupt the autoimmune attack of islets.
The specific aims of the UG3 phase are:
Aim 1: To expand the biomimetic platform.
Aim 2: To develop models of T cell-mediated autoimmunity.
Aim 3: To establish new iPSC lines and novel reporters of B cell stress and death.
The specific aims of the UH3 phase are:
Aim 1: To develop isogenic models of autoimmune T1D.
Aim 2: To identify determinants of islet infiltration and immune killing.
Aim 3: To perform genetic studies of autoimmunity in T1D.
This proposal leverages our group’s complementary expertise in tissue-on-a-chip technology, immunology, pluripotent cell derivation and differentiation, and islet biology to create robust systems containing human islet cells, immune cells, and other features to recapitulate the process of islet autoimmunity in type I diabetes (T1D).
The UG3 phase of this proposal will improve upon already-robust microdevices and develop new cell lines and assays that will enable studies of autoimmunity in an isogenic setting. The UH3 phase of this proposal will exploit these tools and platforms to develop isogenic models that can be used to study immune-islet interactions. The focus of the UH3 phase will be to investigate the determinants of islet infiltration and killing, and to determine the effects of mutations in T1D-associated genes on this process.
In addition, these in vitro systems will be used to pilot the use of cellular therapies to interrupt the autoimmune attack of islets.
The specific aims of the UG3 phase are:
Aim 1: To expand the biomimetic platform.
Aim 2: To develop models of T cell-mediated autoimmunity.
Aim 3: To establish new iPSC lines and novel reporters of B cell stress and death.
The specific aims of the UH3 phase are:
Aim 1: To develop isogenic models of autoimmune T1D.
Aim 2: To identify determinants of islet infiltration and immune killing.
Aim 3: To perform genetic studies of autoimmunity in T1D.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Pennsylvania
United States
Geographic Scope
State-Wide
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 219% from $1,126,584 to $3,590,765.
Trustees Of The University Of Pennsylvania was awarded
Microphysiological systems for modeling autoimmunity in type 1 diabetes
Cooperative Agreement UH3DK122644
worth $3,590,765
from the National Institute of Diabetes and Digestive and Kidney Diseases in August 2019 with work to be completed primarily in Pennsylvania United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
The Cooperative Agreement was awarded through grant opportunity Human Islet Research Network - Consortium on Human Islet Biomimetics (HIRN-CHIB) (UG3/UH3 Clinical Trial Not Allowed).
Status
(Complete)
Last Modified 8/4/23
Period of Performance
8/2/19
Start Date
7/31/24
End Date
Funding Split
$3.6M
Federal Obligation
$0.0
Non-Federal Obligation
$3.6M
Total Obligated
Activity Timeline
Transaction History
Modifications to UH3DK122644
Additional Detail
Award ID FAIN
UH3DK122644
SAI Number
UH3DK122644-948771260
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NK00 NIH NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
Funding Office
75NK00 NIH NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
Awardee UEI
GM1XX56LEP58
Awardee CAGE
7G665
Performance District
PA-03
Senators
Robert Casey
John Fetterman
John Fetterman
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Health and Human Services (075-0884) | Health research and training | Grants, subsidies, and contributions (41.0) | $2,464,181 | 100% |
Modified: 8/4/23